Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

transcreation

- PMLiVE

How to build a commercialisation strategy fit for biopharma’s new evidence era

The bar for evidence has never been higher. The EU's Joint Clinical Assessment process went live in January 2025, introducing harmonised clinical evidence requirements across member states. Regulators are demanding...

Nmblr

- PMLiVE

Roche’s Tecentriq gets FDA Priority Review for specific stage 3 colon cancer

Over one million people are diagnosed globally each year and around 30% of stage 3 patients relapse within five years

- PMLiVE

Oriva Therapeutics appoints Agnès Arbat as CEO

Arbat previously held senior roles in women’s health at Oxolife, Bayer and Organon

UK POM Digital Estate Benchmark

New benchmark reveals significant digital maturity gap across UK POM companies’ product-information estates

A new benchmark maps 100 UK prescription medicine companies across five maturity bands and finds a market at very different stages of digital development

Genetic Digital

- PMLiVE

Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis

This new option for patients allows for as few as six maintenance injections per year

- PMLiVE

The next frontier in clinical trials: navigating multi-disease research with GLP-1s

As GLP-1s redefine the treatment landscape for obesity, they are also promising candidates to influence a wide range of disease pathways

Man reading pamphlet

Where translation falls short in practice

Discover why translation alone is not enough in global clinical trials and how expert localisation improves participant understanding, trust and engagement.

Cuttsy + Cuttsy

- PMLiVE

GSK to acquire biopharma Nuvalent for $10.6bn

Two of Nuvalent’s NSCLC therapies have received FDA Breakthrough Therapy and Orphan Drug Designations

- PMLiVE

CSL’s Privigen approved as measles treatment by European Commission

Cases of measles have been rising in Europe since 2023

- PMLiVE

Roche and Nurix Therapeutics to partner in $2.3bn deal

The companies will co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology

- PMLiVE

Headline trade and market deals are opening doors to greater patient access

Regulatory changes and tariffs have created a positive climate for investment, innovation and, critically, patient access to therapies

- PMLiVE

Biogen’s salanersen gets FDA Breakthrough Therapy Designation for SMA

In the study, there were improvements in motor function as well as a slowing of neurodegeneration

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links